vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $132.6M, roughly 1.4× Urban Edge Properties). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 12.2%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 11.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
AXSM vs UE — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $132.6M |
| Net Profit | — | $22.6M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 17.1% |
| Revenue YoY | 57.4% | 12.2% |
| Net Profit YoY | — | -6.7% |
| EPS (diluted) | — | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $132.6M | ||
| Q4 25 | $196.0M | $119.6M | ||
| Q3 25 | $171.0M | $120.1M | ||
| Q2 25 | $150.0M | $114.1M | ||
| Q1 25 | $121.5M | $118.2M | ||
| Q4 24 | $118.8M | $116.4M | ||
| Q3 24 | $104.8M | $112.4M | ||
| Q2 24 | $87.2M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $-28.6M | $12.4M | ||
| Q3 25 | $-47.2M | $14.9M | ||
| Q2 25 | $-48.0M | $58.0M | ||
| Q1 25 | $-59.4M | $8.2M | ||
| Q4 24 | $-74.9M | $30.1M | ||
| Q3 24 | $-64.6M | $9.1M | ||
| Q2 24 | $-79.3M | $30.8M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 11.3% | ||
| Q3 25 | -27.0% | 13.4% | ||
| Q2 25 | -24.5% | 53.9% | ||
| Q1 25 | -46.9% | 7.6% | ||
| Q4 24 | -61.1% | 27.6% | ||
| Q3 24 | -59.8% | 8.9% | ||
| Q2 24 | -89.5% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | -14.6% | 10.4% | ||
| Q3 25 | -27.6% | 12.4% | ||
| Q2 25 | -32.0% | 50.8% | ||
| Q1 25 | -48.9% | 6.9% | ||
| Q4 24 | -63.1% | 25.9% | ||
| Q3 24 | -61.7% | 8.1% | ||
| Q2 24 | -91.0% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $-0.55 | $0.09 | ||
| Q3 25 | $-0.94 | $0.12 | ||
| Q2 25 | $-0.97 | $0.46 | ||
| Q1 25 | $-1.22 | $0.07 | ||
| Q4 24 | $-1.54 | $0.25 | ||
| Q3 24 | $-1.34 | $0.07 | ||
| Q2 24 | $-1.67 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $50.0M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.4B |
| Total Assets | $713.6M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $50.0M | ||
| Q4 25 | $322.9M | $48.9M | ||
| Q3 25 | $325.3M | $77.8M | ||
| Q2 25 | $303.0M | $53.0M | ||
| Q1 25 | $300.9M | $48.0M | ||
| Q4 24 | $315.4M | $41.4M | ||
| Q3 24 | $327.3M | $67.9M | ||
| Q2 24 | $315.7M | $78.6M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $88.3M | $1.4B | ||
| Q3 25 | $73.7M | $1.4B | ||
| Q2 25 | $73.1M | $1.4B | ||
| Q1 25 | $53.2M | $1.4B | ||
| Q4 24 | $57.0M | $1.4B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.3B |
| Q1 26 | $713.6M | $3.4B | ||
| Q4 25 | $689.8M | $3.3B | ||
| Q3 25 | $669.3M | $3.3B | ||
| Q2 25 | $639.8M | $3.3B | ||
| Q1 25 | $596.7M | $3.3B | ||
| Q4 24 | $568.5M | $3.3B | ||
| Q3 24 | $561.5M | $3.2B | ||
| Q2 24 | $548.2M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $39.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $-18.7M | $182.7M | ||
| Q3 25 | $1.0M | $55.7M | ||
| Q2 25 | $-32.4M | $43.5M | ||
| Q1 25 | $-43.4M | $32.6M | ||
| Q4 24 | $-26.2M | $153.2M | ||
| Q3 24 | $-18.6M | $36.6M | ||
| Q2 24 | $-30.1M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $81.8M | ||
| Q3 25 | $988.0K | $26.1M | ||
| Q2 25 | $-32.4M | $19.6M | ||
| Q1 25 | $-43.7M | $11.9M | ||
| Q4 24 | $-26.2M | $42.5M | ||
| Q3 24 | $-18.7M | $12.2M | ||
| Q2 24 | $-30.2M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 68.4% | ||
| Q3 25 | 0.6% | 21.7% | ||
| Q2 25 | -21.6% | 17.2% | ||
| Q1 25 | -36.0% | 10.0% | ||
| Q4 24 | -22.1% | 36.6% | ||
| Q3 24 | -17.9% | 10.8% | ||
| Q2 24 | -34.6% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 0.0% | 84.4% | ||
| Q3 25 | 0.0% | 24.6% | ||
| Q2 25 | 0.0% | 20.9% | ||
| Q1 25 | 0.3% | 17.5% | ||
| Q4 24 | 0.0% | 95.1% | ||
| Q3 24 | 0.1% | 21.7% | ||
| Q2 24 | 0.1% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 14.71× | ||
| Q3 25 | — | 3.73× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 3.97× | ||
| Q4 24 | — | 5.09× | ||
| Q3 24 | — | 4.03× | ||
| Q2 24 | — | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
